Year: 2022
Type: editorial
Abstract: A microencapsulated, cell-based IL2 cytokine factory was recently developed, and the safety and efficacy of this platform in a mouse model of mesothelioma were demonstrated. This platform has the potential to overcome current challenges in the delivery of therapeutic cytokines for cancer immunotherapy. See related article by Nash et al., p. 5121.
Source: Clinical Cancer Research
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: National Science Foundation, Burroughs Wellcome Fund, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, Division of Chemical, Bioengineering, Environmental, and Transport Systems, National Center for Advancing Translational Sciences
Awards: A data-driven drug delivery (4D) platform for probing and treating the chemoresistant bone marrow microenvironment, G1343596579, G185654730, G2848036350, G3015188539, Graduate Research Fellowship Program(GRFP), In utero gene editing to cure a metabolic liver disease, G6671297155, Modular approach for the delivery of antibodies into the cytoplasm of cells, CAREER: Nanoparticle mRNA and DNA Immunoengineering of Macrophages for Solid Tumor Targeting, Ionizable Lipid Nanoparticles for Fetal Lung Targeting, Targeting stem-like cells and their niche in pancreatic cancer
OpenAlex ID: W4300688601